Table 4.
Treatments and outcomes
| Pt no. Age/Gender | Neurological syndrome, cancer, or other potential trigger | Treatment (time to treatment, months) | Outcome |
|---|---|---|---|
| 1. M/77 | Encephalopathy, URI | None | Died |
| 2. F/47* | Encephalopathy, SCLC | Steroids, rituximab, azathioprine (1) | Resolved |
| 3. M/52* | Encephalopathy | Steroids, IVIg (3) | Worsened |
| 4. F/74* | Encephalopathy, Merkel cell | Steroids, IVIG, Rituximab, cyclophosphamide (6) | Improved |
| 7. M/41 | Encephalopathy, enterovirus | None | Died |
| 8. F/66 | Encephalopathy, HIV | None | Died |
| 10. M/55 | Encephalopathy | Steroids | Improved |
| 11. M/47 | Encephalopathy, ehrlichosis | None | Spontaneous improvement |
| 12. M/63* | Encephalopathy, papillary renal cell carcinoma | Rituximab, steroids (3) | Resolved |
| 13. F/75 | Encephalopathy & ataxia, Merkel cell | Steroids | Improved |
| 14. F/60* | Encephalopathy | IVIg, Steroids, Rituximab (4) | Worsened, died |
| 15. M/79 | Encephalopathy, hepatocellular carcinoma | None | Died** |
| 16. F/73* | Encephalopathy, ehrlichosis | None | Spontaneous resolution |
| 17. M/69 | Encephalopathy | PLEX, steroids, and rituximab | Worsened |
| 18. F/43 | Encephalopathy & ataxia, HIV | None | Spontaneous resolution |
| 19. M/88* | Encephalopathy & ataxia, pancreas neuroendocrine | None | Died** |
| 21. F/48* | Encephalomyelopathy | Steroids | Resolved |
| 22. M/57 | Encephalomyelopathy, lung rhabdoid adenocarcinoma | Steroids | Resolved |
| 23. M/21 | Encephalomyelopathy |
Attack 1: None; Attack 2: steroids (1) |
Resolved on both occasions |
| 24. F/81 | Ataxia, Hodgkin lymphoma | Chemotherapy | Improved |
| 26. F/74 | Ataxia, Merkel cell | Rituximab | Worsened, died** |
| 27. M/64 | Ataxia, SCLC | IVIg | Improved |
| 28. F/74* | Ataxia, Merkel cell | Steroids, Rituximab, cyclophosphamide (1) | Improved, but profound disability (walker or wheelchair) |
| 29. M/65 | Ataxia, Merkel cell carcinoma | Steroids, Chemotherapy | Improved |
| 30. M/64 | Ataxia, SCLC | Steroids | Improved |
| 33. M/56 | Spinocerebellar, SCLC | None | Spontaneous improvement |
| 34. F/61* | Bulbospinal | PLEX (5) | No response to PLEX. Fluctuating course, PEG dependent |
| 35. M/64* | Myelitis, ehrlichia | Steroids, PLEX (1) | Resolved |
| 38. M/59* | Myeloneuropathy | IVIg, rituximab (36) | Worsened. Progression of symptoms from lower to upper extremities |
| 39. F/43 | Lumbosacral polyradiculoneuropathy | None | Spontaneous improvement |
| 40. M/65* | Lumbosacral polyradiculoneuropathy, NHL | None | Worsened |
F, female; IVIg, intravenous immunoglobulin; M, male; NHL, non‐Hodgkin lymphoma; PLEX, plasma exchange; Pt no., patient number; URI, upper respiratory tract infection; SCLC, small cell carcinoma.
*
Evaluated at Mayo Clinic.
**
Died from cancer.